Key facts
- Notable investors include Tech Incubator Program for Startup, InfoBank, Inwoo Hyung, Korea Biotech Investment Capital, iAccel (Seongnam-si).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for KSB Tugen
- ·The full record, as it builds
Funding rounds
No funding rounds for KSB Tugen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KSB Tugen
Developer of therapeutics designed to provide treatment for intractable sarcopenia based on clinical multi-omics. The company's therapeutics provide senile sarcopenia treatment that helps to fight against diseases, enabling healthcare companies to provide patients with treatment services.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 7
- Website
- ksbtugen.com/
- Ownership
- Privately Held (backing)
KSB Tugen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KSB Tugen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KSB Tugen in its N-PORT filings yet. We sweep new filings monthly.